Filter Results:
- Full text PDF available (21)
Publication Year
1990
2018
- This year (5)
- Last 5 years (21)
- Last 10 years (33)
Publication Type
Co-author
Journals and Conferences
Learn More
- William H D Hallett, Weiqing Jing, William R. Drobyski, Bryon D. Johnson
- Biology of blood and marrow transplantation…
- 2011
Multiple myeloma is an incurable plasma cell malignancy. Patients who fail conventional therapy are frequently treated with hematopoietic stem cell transplantation (HSCT), which results in reduced… (More)
- Robert L. Truitt, Bryon D. Johnson, Carrie A Hanke, Sohel Talib, J. E. Hearst
- Journal of immunology
- 1999
Donor leukocyte infusions after allogeneic bone marrow transplantation can provide a curative graft-vs-leukemia (GVL) effect, but there is a significant risk of graft-vs-host (GVH) disease. A simple… (More)
- Qizhen Shi, David A. Wilcox, +5 authors Robert R. Montgomery
- Journal of thrombosis and haemostasis : JTH
- 2007
BACKGROUND
Previous studies from our laboratory have demonstrated that lineage-targeted synthesis of factor VIII (FVIII) under the direction of the platelet-specific integrin alphaIIb gene promoter… (More)
- Bryon D. Johnson, Marja C Konkol, Robert L. Truitt
- Biology of blood and marrow transplantation…
- 2002
We have previously identified donor-derived Thy1+ alphabeta T-cell receptor (TCR)+ CD4+ CD8- regulatory T-cells that suppress GVH reactivity induced by donor leukocyte infusion (DLI) after BMT. These… (More)
- Tyce J. Kearl, Weiqing Jing, Jill A. Gershan, Bryon D. Johnson
- Journal of immunology
- 2013
Early phase clinical trials targeting the programmed death receptor-1/ligand-1 (PD-1/PD-L1) pathway to overcome tumor-mediated immunosuppression have reported promising results for a variety of… (More)
- Bryon D. Johnson, Emily E. Becker, Robert L. Truitt
- Biology of blood and marrow transplantation…
- 1999
Infusions of donor leukocytes have been given to allogeneic bone marrow recipients after transplant to treat leukemia relapse. Treatment with these delayed infusions of donor cells has been called… (More)
- Rimas J. Orentas, David A Schauer, Qian Bin, Bryon D. Johnson
- Cellular immunology
- 2001
The absence of surface costimulatory molecules explains in part the lack of an effective anti-tumor immune response in tumor-bearing animals, even though unique tumor antigens may be presented by… (More)
- Rimas J. Orentas, M. Eric Kohler, Bryon D. Johnson
- Seminars in cancer biology
- 2006
Suppressor/regulatory T cells were first shown to have an impact on cancer progression in experimental tumor models during the 1970s. However, the lack of specific markers hindered mechanistic… (More)
- Meghen B Browning, Jeffrey E. Woodliff, +4 authors Bryon D. Johnson
- Cellular immunology
- 2004
We have been investigating whether alloantigen-specific CD4(+)25+ regulatory T cells can be identified for use in treating graft-versus-host disease. CD150, which is upregulated on the surface of all… (More)
- Viswanath P. Kurup, Christy S. Barrios, Raghavan Raju, Bryon D. Johnson, Michael B. Levy, Jordan N. Fink
- Clinical and molecular allergy : CMA
- 2007
BACKGROUND
There has been a worldwide increase in allergy and asthma over the last few decades, particularly in industrially developed nations. This resulted in a renewed interest to understand the… (More)